Works by Mahadevan, Daruka

Results: 60
    1
    2

    Phase I Trial of Cemiplimab, Radiotherapy, Cyclophosphamide, and Granulocyte Macrophage Colony‐Stimulating Factor in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.

    Published in:
    Oncologist, 2021, v. 26, n. 9, p. e1508, doi. 10.1002/onco.13810
    By:
    • Babiker, Hani;
    • Brana, Irene;
    • Mahadevan, Daruka;
    • Owonikoko, Taofeek;
    • Calvo, Emiliano;
    • Rischin, Danny;
    • Moreno, Victor;
    • Papadopoulos, Kyriakos P.;
    • Crittenden, Marka;
    • Formenti, Silvia;
    • Giralt, Jordi;
    • Garrido, Pilar;
    • Soria, Ainara;
    • Hervás‐Morón, Asunción;
    • Mohan, Kosalai Kal;
    • Fury, Matthew;
    • Lowy, Israel;
    • Mathias, Melissa;
    • Feng, Minjie;
    • Li, Jingjin
    Publication type:
    Article
    3

    Academic Cancer Center Phase I Program Development.

    Published in:
    Oncologist, 2017, v. 22, n. 4, p. 369, doi. 10.1634/theoncologist.2016-0409
    By:
    • Frankel, Arthur E.;
    • Flaherty, Keith T.;
    • Weiner, George J.;
    • Chen, Robert;
    • Azad, Nilofer S.;
    • Pishvaian, Michael J.;
    • Thompson, John A.;
    • Taylor, Matthew H.;
    • Mahadevan, Daruka;
    • Lockhart, A. Craig;
    • Vaishampayan, Ulka N.;
    • Berlin, Jordan D.;
    • Smith, David C.;
    • Sarantopoulos, John;
    • Riese, Matthew;
    • Saleh, Mansoor N.;
    • Ahn, Chul;
    • Frenkel, Eugene P.
    Publication type:
    Article
    4
    5

    Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia.

    Published in:
    Leukemia & Lymphoma, 2012, v. 53, n. 3, p. 417, doi. 10.3109/10428194.2011.618232
    By:
    • Wendtner, Clemens-Martin;
    • Hillmen, Peter;
    • Mahadevan, Daruka;
    • Bühler, Andreas;
    • Uharek, Lutz;
    • Coutré, Steven;
    • Frankfurt, Olga;
    • Bloor, Adrian;
    • Bosch, Francesc;
    • Furman, Richard R.;
    • Kimby, Eva;
    • Gribben, John G.;
    • Gobbi, Marco;
    • Dreisbach, Luke;
    • Hurd, David D.;
    • Sekeres, Mikkael A.;
    • Ferrajoli, Alessandra;
    • Shah, Sheetal;
    • Zhang, Jennie;
    • Moutouh-de Parseval, Laure
    Publication type:
    Article
    6

    Pharmacotherapeutic options for pancreatic ductal adenocarcinoma.

    Published in:
    Expert Opinion on Pharmacotherapy, 2022, v. 23, n. 18, p. 2079, doi. 10.1080/14656566.2022.2149322
    By:
    • Sardar, Muhammad;
    • Recio-Boiles, Alejandro;
    • Mody, Kabir;
    • Karime, Christian;
    • Chandana, Sreenivasa R;
    • Mahadevan, Daruka;
    • Starr, Jason;
    • Jones, Jeremy;
    • Borad, Mitesh;
    • Babiker, Hani
    Publication type:
    Article
    7
    8
    9
    10

    Phase 1b study of safety, tolerability and efficacy of R1507, a monoclonal antibody to IGF-1R in combination with multiple standard oncology regimens in patients with advanced solid malignancies.

    Published in:
    Cancer Chemotherapy & Pharmacology, 2014, v. 73, n. 3, p. 467, doi. 10.1007/s00280-013-2372-x
    By:
    • Mahadevan, Daruka;
    • Sutton, Gregory;
    • Arteta-Bulos, Rafael;
    • Bowden, Chris;
    • Miller, Paul;
    • Swart, Rachel;
    • Walker, Mark;
    • Haluska, Paul;
    • Munster, Pamela;
    • Marshall, John;
    • Hamid, Omid;
    • Kurzrock, Razelle
    Publication type:
    Article
    11
    12
    13
    14

    A Multidisciplinary Evaluation of Barriers to Enrolling Cancer Patients into Early Phase Clinical Trials: Challenges and Patient-centric Recommendations.

    Published in:
    Expert Opinion on Investigational Drugs, 2019, v. 28, n. 8, p. 675, doi. 10.1080/13543784.2019.1646726
    By:
    • Babiker, Hani M;
    • Davis, Lisa;
    • Larson, Kristian;
    • Placencia, Crystal;
    • Swensen, Connor;
    • Tenneti, Pavan;
    • Lim, Melissa;
    • Cañamar, Ruth;
    • Curtis, Jacqueline;
    • Castillo, Erica;
    • Mancuso, James;
    • Rensvold, Diane;
    • Martinez, Sarah;
    • Macias, Lora;
    • Recio-Boiles, Alejandro;
    • Chandana, Sreenivasa R;
    • Mahadevan, Daruka
    Publication type:
    Article
    15
    16
    17
    18
    19

    Gene Expression Patterns Associated with Survival in Glioblastoma.

    Published in:
    International Journal of Molecular Sciences, 2024, v. 25, n. 7, p. 3668, doi. 10.3390/ijms25073668
    By:
    • Morrison, Christopher;
    • Weterings, Eric;
    • Gravbrot, Nicholas;
    • Hammer, Michael;
    • Weinand, Martin;
    • Sanan, Abhay;
    • Pandey, Ritu;
    • Mahadevan, Daruka;
    • Stea, Baldassarre
    Publication type:
    Article
    20
    21
    22
    23
    24
    25
    26
    27
    28
    29
    30
    31
    32
    33

    A multicenter phase 1/2 study investigating the safety, pharmacokinetics, pharmacodynamics and efficacy of a small molecule antimetabolite, RX-3117, plus nab-paclitaxel in pancreatic adenocarcinoma.

    Published in:
    Investigational New Drugs, 2022, v. 40, n. 1, p. 81, doi. 10.1007/s10637-021-01164-9
    By:
    • Babiker, Hani;
    • Schlegel, Peter J.;
    • Hicks, Lee G.;
    • Bullock, Andrea J.;
    • Burhani, Nafisa;
    • Mahadevan, Daruka;
    • Elquza, Emad;
    • Borad, Mitesh J.;
    • Benaim, Ely;
    • Peterson, Christine;
    • Heaton, Callie;
    • Ocean, Allyson J.
    Publication type:
    Article
    34
    35
    36
    37
    38
    39
    40
    41
    42
    43
    44
    45

    Cross-Resistance to Abiraterone and Enzalutamide in Castration Resistance Prostate Cancer Cellular Models Is Mediated by AR Transcriptional Reactivation.

    Published in:
    Cancers, 2021, v. 13, n. 6, p. 1483, doi. 10.3390/cancers13061483
    By:
    • Simon, Iris;
    • Perales, Sonia;
    • Casado-Medina, Laura;
    • Rodríguez-Martínez, Alba;
    • Garrido-Navas, Maria del Carmen;
    • Puche-Sanz, Ignacio;
    • Diaz-Mochon, Juan J.;
    • Alaminos, Clara;
    • Lupiañez, Pablo;
    • Lorente, Jose A.;
    • Serrano, María J.;
    • Real, Pedro J.;
    • Mahadevan, Daruka
    Publication type:
    Article
    46
    47

    A phase 1/2 trial of ublituximab, a novel anti- CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab.

    Published in:
    British Journal of Haematology, 2017, v. 177, n. 2, p. 243, doi. 10.1111/bjh.14534
    By:
    • Sawas, Ahmed;
    • Farber, Charles M.;
    • Schreeder, Marshall T.;
    • Khalil, Mazen Y.;
    • Mahadevan, Daruka;
    • Deng, Changchun;
    • Amengual, Jennifer E.;
    • Nikolinakos, Petros G.;
    • Kolesar, Jill M.;
    • Kuhn, John G.;
    • Sportelli, Peter;
    • Miskin, Hari P.;
    • O'Connor, Owen A.
    Publication type:
    Article
    48

    Ublituximab ( TG-1101), a novel glycoengineered anti- CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial.

    Published in:
    British Journal of Haematology, 2017, v. 176, n. 3, p. 412, doi. 10.1111/bjh.14447
    By:
    • Sharman, Jeff P.;
    • Farber, Charles M.;
    • Mahadevan, Daruka;
    • Schreeder, Marshall T.;
    • Brooks, Heather D.;
    • Kolibaba, Kathryn S.;
    • Fanning, Suzanne;
    • Klein, Leonard;
    • Greenwald, Daniel R.;
    • Sportelli, Peter;
    • Miskin, Hari P.;
    • Weiss, Michael S.;
    • Burke, John M.
    Publication type:
    Article
    49
    50

    A call to arms: Unifying the fight against resistance.

    Published in:
    2018
    By:
    • Kaushansky, Alexis;
    • Hedstrom, Lizbeth;
    • Goldman, Aaron;
    • Singh, Juswinder;
    • Yang, Priscilla L.;
    • Rathod, Pradipsinh K.;
    • Cynamon, Michael;
    • Wodarz, Dominik;
    • Mahadevan, Daruka;
    • Tomaras, Andrew;
    • Navia, Manuel A.;
    • Schiffer, Celia A.
    Publication type:
    Editorial